{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:27Z","timestamp":1787026587454,"version":"build-2736575974"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    This study aimed to investigate drug retention rates for various TNF inhibitors (TNFis) commonly prescribed to Korean patients with ankylosing spondylitis (AS) in the Korean College of Rheumatology Biologics registry (KOBIO; December 2012\u2013June 2016). Discontinuation was defined as switching or stopping the biologic agent. Kaplan\u2013Meier curves and Cox's proportional hazard models were used for further analysis. The reasons for discontinuation of TNFis were also assessed. Univariate and multivariate analyses were used to identify possible predictors of discontinuation. Data from 1,005 patients with AS were analyzed with a median follow-up period of 14 months. Seventy-six percent of patients were first-line biologic users. Discontinuation of TNFis occurred in 24.2% (switching in 9.6%) of patients during follow-up. An estimate of the drug failure showed that the adjusted hazard ratio (HR) for golimumab compared to etanercept was 0.441 (95% confidence interval: 0.277\u20130.703,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001). Reasons for discontinuation included lack of efficacy (32.6%), adverse events (23.6%), clinical improvement (11.2%), and others (32.6%). Predictors of discontinuation using a multivariate analysis were a shorter disease duration (HR: 0.973,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.044) and being negative for HLA-B27 (HR: 1.623,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0093). In conclusion, few Korean patients with AS switched to other TNFis during their treatment. The drug retention rate for golimumab was higher than for other agents.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2021.689609","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T03:57:15Z","timestamp":1623729435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of Retention Rates Between Tumor Necrosis Factor-\u03b1 Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry"],"prefix":"10.3389","volume":"8","author":[{"given":"Hyoun-Ah","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kichul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"New Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3111\/13696998.2012.660255","article-title":"Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials","volume":"15","author":"Migliore","year":"2012","journal-title":"J Med Econ."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study","volume":"74","author":"Deodhar","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/rheumatology\/ker087","article-title":"The ankylosing spondylitis disease activity score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-alpha inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China","volume":"50","author":"Xu","year":"2011","journal-title":"Rheumatology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20090","article-title":"Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation","volume":"20","author":"Corbett","year":"2016","journal-title":"Health Technol Assess."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0194130","DOI":"10.1371\/journal.pone.0194130","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis - the ANSWER cohort study","volume":"13","author":"Ebina","year":"2018","journal-title":"PLoS One."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s10067-016-3349-z","article-title":"Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability","volume":"35","author":"Iannone","year":"2016","journal-title":"Clin Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","article-title":"Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry","volume":"68","author":"Favalli","year":"2016","journal-title":"Arthritis Care Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1756-185X.12264","article-title":"Factors associated with withdrawal of the anti-TNFalpha biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry","volume":"17","author":"Mok","year":"2014","journal-title":"Int J Rheum Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14397595.2017.1332558","article-title":"Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: a multicenter observational cohort study","volume":"28","author":"Asai","year":"2018","journal-title":"Mod Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/ddr.21192","article-title":"Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides","volume":"75","author":"Biggioggero","year":"2014","journal-title":"Drug Dev Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4078\/jrd.2017.24.5.287","article-title":"Comparison of the disease activity score-28 based on the erythrocyte sedimentation rate and C-reactive protein in rheumatoid arthritis","volume":"24","author":"Choi","year":"2017","journal-title":"J Rheum Dis."},{"key":"B15","first-page":"1022","article-title":"Effect of tumour necrosis factor-alpha inhibitors on renal function in patients with rheumatoid arthritis from the KOBIO registry from 2012 to 2016","volume":"36","author":"Kim","year":"2018","journal-title":"Clin Exp Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10067-017-3584-y","article-title":"Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry","volume":"36","author":"Park","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum."},{"key":"B18","first-page":"857","article-title":"Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database","volume":"31","author":"Scire","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0950-3579(05)80305-X","article-title":"The epidemiology of drug treatment failure in rheumatoid arthritis","volume":"9","author":"Wolfe","year":"1995","journal-title":"Baillieres Clin Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/annrheumdis-2019-215427","article-title":"Treatment response and drug retention rates in 24 195 biologic-na\u00efve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration","volume":"78","author":"\u00d8rnbjerg","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"862969","DOI":"10.1155\/2014\/862969","article-title":"Drug retention rates and treatment discontinuation among anti-TNF-alpha agents in psoriatic arthritis and ankylosing spondylitis in clinical practice","volume":"2014","author":"Fabbroni","year":"2014","journal-title":"Mediators Inflamm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","article-title":"Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis","volume":"47","author":"Iannone","year":"2017","journal-title":"Sem Arthritis Rheum."},{"key":"B23","first-page":"804","article-title":"Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry","volume":"35","author":"Manara","year":"2017","journal-title":"Clin Exp Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/acr.23090","article-title":"Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis","volume":"69","author":"Favalli","year":"2017","journal-title":"Arthritis Care Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.689609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T03:57:19Z","timestamp":1623729439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.689609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":25,"alternative-id":["10.3389\/fmed.2021.689609"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.689609","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]},"article-number":"689609"}}